A novel transient receptor potential C3/C6 selective activator induces the cellular uptake of antisense oligonucleotides
Nucleic Acids Research · 2024
DOI: 10.1093/nar/gkae245 ↗Kurz gefasst
Fachartikel in der Zeitschrift Nucleic Acids Research, 2024. Verfasst von Hiroto Kohashi und 8 weiteren Autor:innen. Beteiligte Einrichtung: Graduate School of Pharmaceutical Sciences, Osaka University, Osaka 565-0871, Japan. Hauptthemen laut MEDLINE: Oligonucleotides, Antisense, TRPC Cation Channels, Calcium. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Agency for Medical Research and Development, Osaka University.
Abstract (Originalsprache)
Antisense oligonucleotide (ASO) therapy is a novel therapeutic approach in which ASO specifically binds target mRNA, resulting in mRNA degradation; however, cellular uptake of ASOs remains critically low, warranting improvement. Transient receptor potential canonical (TRPC) channels regulate Ca2+ influx and are activated upon stimulation by phospholipase C-generated diacylglycerol. Herein, we report that a novel TRPC3/C6/C7 activator, L687, can induce cellular ASO uptake. L687-induced ASO uptake was enhanced in a dose- and incubation-time-dependent manner. L687 enhanced the knockdown activity of various ASOs both in vitro and in vivo. Notably, suppression of TRPC3/C6 by specific siRNAs reduced ASO uptake in A549 cells. Application of BAPTA-AM, a Ca2+ chelator, and SKF96365, a TRPC3/C6 inhibitor, suppressed Ca2+ influx via TRPC3/C6, resulting in reduced ASO uptake, thereby suggesting that Ca2+ influx via TRPC3/C6 is critical for L687-mediated increased ASO uptake. L687 also induced dextran uptake, indicating that L687 increased endocytosis. Adding ASO to L687 resulted in endosome accumulation; however, the endosomal membrane disruptor UNC7938 facilitated endosomal escape and enhanced knockdown activity. We discovered a new function for TRPC activators regarding ASO trafficking in target cells. Our findings provide an opportunity to formulate an innovative drug delivery system for the therapeutic development of ASO.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Graduate School of Pharmaceutical Sciences, Osaka University, Osaka 565-0871, Japan.
- School of Pharmaceutical Sciences, Osaka University, Osaka 565-0871, Japan.
- Graduate School of Engineering, Kyoto University, Kyoto 615-8510, Japan.
- National Institutes of Biomedical Innovation, Health and Nutrition, Osaka 567-0085, Japan.
- Institute for Open and Transdisciplinary Research Initiatives (OTRI), Osaka University, Osaka 565-0871, Japan.
ORCID-Profile: Yusuke Tamenori, Satoshi Obika, Masahito Shimojo
Förderung
- Japan Agency for Medical Research and Development
- Osaka University
Zitieren
APA
Kohashi, H., Nagata, R., Tamenori, Y., Amatani, T., Ueda, Y., Mori, Y., Kasahara, Y., Obika, S., & Shimojo, M. (2024). A novel transient receptor potential C3/C6 selective activator induces the cellular uptake of antisense oligonucleotides. Nucleic Acids Research. https://doi.org/10.1093/nar/gkae245
Vancouver
Kohashi H, Nagata R, Tamenori Y, Amatani T, Ueda Y, Mori Y, et al. A novel transient receptor potential C3/C6 selective activator induces the cellular uptake of antisense oligonucleotides. Nucleic Acids Research. 2024. doi:10.1093/nar/gkae245
BibTeX
@article{Kohashi2024,
author = {Kohashi, Hiroto and Nagata, Ryu and Tamenori, Yusuke and Amatani, Tomorrow and Ueda, Yoshifumi and Mori, Yasuo and Kasahara, Yuuya and Obika, Satoshi and Shimojo, Masahito},
title = {A novel transient receptor potential C3/C6 selective activator induces the cellular uptake of antisense oligonucleotides},
journal = {Nucleic Acids Research},
year = {2024},
doi = {10.1093/nar/gkae245}
}
EUVIMED